AndhraNews.net
Home » Features » Health » HIV

HIV


Human immunodeficiency virus (HIV) is a lentivirus that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

The virus infects human being and leads to problems with their immune system.

Obligation to disclose HIV to sexual partners

In the United States, it is illegal not to disclose HIV status to sexual partners in more than 30 states.

Not always a crime in Canada

On 5 October 2012, the Supreme Court of Canada has ruled that it is not always a crime for people with HIV to not disclose their HIV status to their sex partners. The court opined that as long as they have a low level of virus and wear a condom, they are not obligated to disclose their HIV status. Charges could still be laid against those reckless and fail to take steps to avoid transmission of the virus.

The court arrived at the decision 9-0.

Earlier in 1998, a court has ruled that those who fail to disclose HIV status could be charged with sexual assault or aggravated sexual assault if there is a significant risk of bodily harm.

Research and Studies

HIV becoming immune to vaccines

According to scientists who studied evolution in North America, HIV virus is slowly adapting over time to its human hosts. Researches have studied HIV from patients dating from 1979 which is the beginning of the North American HIV epidemic. They reconstructed epidemic's ancestral HIV sequence and assessed the spread. Results showed that virus is adapting very slowly in North America. The rates of adaptation could be higher in other parts of the world, said the study. Apr 27, 2014

HIV in News

VIVUS, Inc. Announces Intent to Reacquire U.S. and Canadian Rights for Stendra(R) (Avanafil)
MOUNTAIN VIEW, CA--(Marketwired - December 31, 2015) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that it has been notified by Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International, plc., of Auxilium's intention to return the U.S. and Canadian commercial rights for STENDRA® (Avanafil) to VIVUS

Nutra Pharma Letter to Shareholders

The New England Journal of Medicine publishes "Selexipag for the treatment of pulmonary arterial hypertension"
Actelion Pharmaceuticals Ltd /The New England Journal of Medicine publishes "Selexipag for the treatment of pulmonary arterial hypertension" . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Actelion receives US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension
Actelion Pharmaceuticals Ltd /Actelion receives US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Cannabis Science Recaps "Your Money's Worth" Radio Interview: The Company Spoke of Its Market Prioritization, Progress to-Date, and Strategic Planning Moving Forward
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, was a featured guest on the long-running radio show, "Your Money's Worth" on Friday, December 18th, where they discussed the efficacy of cannabis-based treatments, the company's progress, and its strategy moving forward.

Bionor announces that the HIV 'Shock & Kill' trial REDUC with Vacc-4x and romidepsin meets its primary endpoint by significantly reducing latent HIV reservoir and demonstrates control of viral load
BIONOR PHARMA ASA

Cannabis Science (OTC PINK: CBIS) to Be a Featured Guest on "Your Money's Worth" National Radio Show, Tonight From 5-7 PM (EST) on 1470 AM, WWNN Radio South Florida, as Well as Live Internet Streaming
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, will be a featured guest tonight on "Your Money's Worth," a long-running radio show hosted by business and sports broadcaster, Mick "The Mixter" Bazsuly

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTCQB: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www

After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTCQB: IMCL).

Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite
Nutra Pharma Corp. (the "Company") (OTCQB: NPHC), a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks

Cannabis Science Enters Select, New High-Dosage Product Line of CBD, Sativa, and Indica Capsules Into the Industry-Famous Emerald Cup Event This Weekend in Santa Rosa, CA
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, will debut, represent, and compete at The Emerald Cup competitions for the prestigious awards. Cannabis Science has entered 3 products into 2 categories

Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis

GeoVax Begins Oncology Immunotherapy Program
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today that it has begun a new program to evaluate its MVA-VLP vaccine platform for use in cancer immunotherapy, and has entered into a Collaborative Research Agreement with the University of Pittsburgh for selection and testing of vaccine candidates.

Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

Progressive Care Inc.: PharmCo Joins Fight Against Turing Pharmaceuticals With Low-Cost Daraprim Alternative
MIAMI, FL--(Marketwired - December 02, 2015) - Progressive Care Inc

How a Simple Computer Game Can Help Reduce HIV Risk for Teenage Girls
NEW YORK, NY--(Marketwired - December 01, 2015) - To coincide with World AIDS Day, ideas42 shared the results of landmark peer-reviewed work aimed at protecting teenagers from HIV in South Africa, where five million people suffer from the disease.

Cannabis Science Releases Cannabinoid-Formulated Capsule Product Line in California; Initial Capsule Formulations Released Are CBD, Indica, and Sativa
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based formulation, announces the launch of their cannabinoid-formulated capsule product line

Cannabis Science (CBIS) Announces Positive Results in California Test Run of Its Pure Decarboxylated CO2 Oil (PDCO) Released Through the Cannabis Science Research Foundation (CSRF) to 15 Dispensaries & Several Less Fortunate, Self-Medicating Patients for Initial Evaluation
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced positive results from its initial test run of its Pure Decarboxylated CO2 Oil (PDCO) released through the Cannabis Science Research Foundation (CSRF or the Foundation) to 15 dispensaries and several less fortunate self-medicating patients.

Worldwide Achievers Felicitated the Winners of Healthcare Excellence Summit & Awards 2015
Business Wire IndiaWorldwide Achievers has initiated the Healthcare Excellence Summit 2015 association with Care World TV as Broadcast Media Partner and Drug Today Medical Times as Print Media Partner, The event was held at Hotel Radisson Blu, New Delhi on 09th December 2015

Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India
Business Wire IndiaBiocon Ltd, Asia's premier biotechnology company, today announced the introduction of an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of  the innovator product commercialized by Gilead Sciences in the US

Stevia Corp. Confirms Protocol to Produce Synthetic CBD
Stevia Corp

Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension
Actelion Pharmaceuticals Ltd /Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

GeoVax's Chief Scientific Officer Invited to Present at Dubai Scientific Conference
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D. will participate as an invited speaker at the 8th Dubai International Conference for Medical Sciences to be held on December 15-17, 2014 in Dubai, United Arab Emirates. Dr

Bristol-Myers Squibb Makes $1 Million Investment, Joining Johnson & Johnson to Support Sector Transformation for HIV/AIDS Service Organizations
WASHINGTON, DC--(Marketwired - December 02, 2014) - Bristol-Myers Squibb commits $1 million to help AIDS service organizations navigate the new realities of health reform. The investment builds on founding support from Johnson & Johnson that launched the Sector Transformation Initiative at AIDS United in 2012

aden + anais(R) Announces a Special Edition Designer Collection for (aden + anais)RED
NEW YORK, NY--(Marketwired - December 01, 2014) - Global baby brand aden + anais® and (RED)® today announced a designer collaboration with Jessica Alba, Gwen Stefani and Rachel Zoe for a limited edition organic swaddle pack to benefit the Global Fund and empower parents to take action towards an AIDS-free generation

Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension
Actelion Pharmaceuticals Ltd /Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Bank of America Winter Village at Bryant Park Goes (RED) for the Annual Tree Lighting
NEW YORK, NY--(Marketwired - November 24, 2014) - Bank of America Winter Village at Bryant Park will dedicate its annual holiday tree lighting to the fight to eradicate mother-to-child HIV transmission

Dr. Perry Halkitis Speaks at World Aids Day in Washington, D.C.
Dr. Perry N. Halkitis, one of the nation's top experts, will be leading at the forefront of the December 3, 2014, World Aid's Day discussion. He will be addressing a wide spread audience as the proclaimed "Aids Warrior" at the Capitol View Conference Center in Washington, D.C.

Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products life science research and clinical diagnostic products, today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius™ HIV 1/2 Supplemental Assay (test).

UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
Bionor Pharma ASA (OSLO: BIONOR)

ZIVO Bioscience, Inc. (OTCQB: ZIVO) -- Effective Monday, November 10 -- Health Enhancement Products, Inc. Is Now ZIVO Bioscience, Inc. and Begins Trading Under Ticker Symbol ZIVO.QB
ZIVO Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc. (OTCQB: HEPI), begins trading under its new symbol effective today. A Michigan-based biotech firm investigating bioactive compounds extracted from algae cultures, ZIVO has also acquired intellectual property in human wellness

Linkage Biosciences Adds to Board Leadership
Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced the election of Mr. Lewis J. Stuart to the company's Board of Directors. The election reflects Linkage's continued focus on expansion in both domestic and international markets.

VIVUS Reports Third Quarter 2014 Financial Results
MOUNTAIN VIEW, CA--(Marketwired - November 05, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the third quarter ended September 30, 2014 and provided a business update.

ScrubaDub & Community Servings Launch Partnership to Feed the Critically Ill and Get Dirty Cars Off the Street
For the second year in a row, Community Serving's 22nd annual Pie in the Sky campaign is partnering with New England's leading car wash company, ScrubaDub Auto Wash Centers, to help provide home-delivered meals to individuals and families battling life-threatening illness.

MBio Diagnostics, Inc. Awarded Contract for Diagnostic Development With the U.S. Army
MBio Diagnostics, Inc. announced today it was awarded a three-year development contract with the U.S. Army's Walter Reed Army Institute of Research (WRAIR) for the "Development of a Ruggedized Portable Cartridge Reader for Malaria Diagnosis."

Manforce Condoms Launches a New TVC Ad Campaign on World AIDS Day
Manforce Condoms, a brand by Mankind Pharma Ltd., launched its brand new TV Commercial for Manforce More Time condoms on World AIDS Day. Talking about the campaign, R.C. Juneja, Chairman, Mankind Pharma Ltd

Piramal Swasthya Partners with NACO to Launch India’s First National AIDS Helpline - 1097
More than 80 percent of women and approximately 70 percent of men in India do not have comprehensive knowledge about HIV/AIDS. NACP IV goal is to reduce new infections by 50% (2007 Baseline of NACP III) 1097 helpline part of the fourth phase of the National HIV/AIDS Control Programme (NACP IV)

AHF Global World AIDS Day Events Focus On Testing and Treatment
PHOTO: For World AIDS Day, AHF will host over 160 events around the world to promote testing, treatment for HIV/AIDS; international commemorations will launch global campaign to connect twenty million HIV-positive people to treatment by the end of 2020. For more information, visit www.aidshealth

Healthcare Experts Across India Come Together to Fight Pneumonia Amongst the Older Population of the Country
To commemorate World Pneumonia Day 2014, experts across renowned national institutes have initiated a campaign to spread maximum awareness about the symptoms and causes of Pneumonia among the elderly population in India. This campaign is an effort to protect adults aged 50 years and above from the deadly pneumococcal disease and thereby reduce the rate of death caused due to pneumonia

Coca-Cola Invites the World to “SHARE THE SOUND OF AN AIDS FREE GENERATION” and Support (RED)
The Coca-Cola Company, in partnership with (RED), invites people from all over the world to join efforts to help end mother-to-child transmission of HIV with the launch of a new campaign, titled “SHARE THE SOUND OF AN AIDS FREE GENERATION”

Recap of NanoViricides, Inc. CEO Dr. Eugene Seymour Clear Channel Business Talk Radio Interview
NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company today announced that Michael Yorba of Clear Channel's Business Talk Radio Show, The Traders Network, interviewed CEO Dr. Eugene Seymour live on December 19, 2013.

Actelion is granted Marketing Authorisation for Opsumit (macitentan) in Pulmonary Arterial Hypertension (PAH) by the European Commission
Actelion Pharmaceuticals Ltd /Actelion is granted Marketing Authorisation for Opsumit (macitentan) in Pulmonary Arterial Hypertension (PAH) by the European Commission . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

NanoViricides CEO Dr. Eugene Seymour to Be Interviewed on Clear Channel DFW 1190AM
NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company announced today that CEO Dr. Eugene Seymour will be interviewed live by Michal Yorba on Clear Channel Business Talk Radio's Traders Financial Network, Thursday, December 19th, 2013, at 2:00pm CST / 12:00pm PST / 3:00pm EST.

GeoVax Announces $1.65M Private Placement
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series B convertible preferred stock at an aggregate purchase price of $1.65 million

Indi Molecular Expands Seed Round to $1.8 Million With Additional $300K From Asset Management Ventures
Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised an additional $300,000 from a new investor, Asset Management Ventures. With this investment, the company has expanded its seed round to a total of $1.8 million. The round was led by InterWest Partners and joined by several angel investors

Scotiabank Reports Record 2013 Annual Net Income of $6.7 Billion
Scotiabank (TSX: BNS)(NYSE: BNS)

Adconion Direct Partners With HomeAid San Diego and Alpha Project to Provide Shelter and Aid for Local Women
Adconion Direct (http://www.adconiondirect.com), an industry leader in cross channel digital advertising spanning display, video, mobile, email and social media, gathered today in support of HomeAid San Diego to provide housing for local homeless women

Timberline Knolls and The Refuge Bring Feature Documentary Film, The Anonymous People, to Winter Park Community
ORLANDO, FL--(Marketwired - December 03, 2013) - Timberline Knolls Residential Treatment Center and The Refuge, A Healing Place, are hosting a screening of the compelling feature documentary, The Anonymous People. The screening will take place Thursday, December 19 at the Regal Cinemas Winter Park Village Stadium 20 Movie Theater (Screen 1), 510 North Orlando Avenue in Winter Park

TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
TNI BioTech Inc (OTCQB: TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.

ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Connecticut on behalf of investors who purchased Achillion Pharmaceuticals, Inc. ("Achillion" or the "Company") (NASDAQ: ACHN) common stock between August 8, 2012 and September 30, 2013.

GeoVax Appoints Dr. Arban Domi as Director, Vector Development
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced the appointment of Arban Domi, Ph.D., as its Director, Vector Development.

Golden Gate University Students Win Two Gold MarCom Awards
Golden Gate University's Direct & Database Marketing class recently captured two prestigious Gold MarCom Awards in the Association of Marketing & Communications Professionals' annual worldwide creative competition.

'Twas the Night Before Christmas Released in Chinese for the First Time in 189 Years by Awarding Winning Anti-Tobacco Activist
The tobacco epidemic and China according to recent studies:

Viriom Expands Global Licensing Agreement With Roche for Innovative Compound Development for HIV Treatment
Today at the 4th annual Innovative Drug Research and Development in Russia Forum, Viriom LLC -- a ChemRar company announced the signing of a global expansion of Viriom's commercial rights to VM-1500, an innovative Roche candidate NNRTI (non-nucleoside reverse transcriptase inhibitor). In 2009, Viriom and Roche concluded a regional license to VM-1500 for treatment of HIV

Border to Border Across Swaziland to Help the Orphans of Aids
LEEDS, MA--(Marketwired - November 19, 2013) - Young Heroes Foundation (YHF) today revealed plans for Swazi Cycle V, its fifth annual bicycle trip through the beautiful, peaceful African kingdom of Swaziland. The trip will take place from May 21 - June 2, 2014.

GeoVax Chief Scientific Officer Lectures at the Texas A&M Health Science Center College of Medicine
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced that Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented the 20th Annual Jesse D. Ibarra, Jr., MD Lectureship in International Health at Scott and White Healthcare and the Texas A&M Health Science Center (TAMHSC) College of Medicine

Cong. Slaughter Visits OyaGen Labs; Encourages Support for HIV a Functional Cure for HIV and the Growth of Biotech in Upstate NY
OyaGen announced today Congresswoman Louise Slaughter toured its laboratories at the Rochester BioVenture Center in Henrietta and met with its development team. During the visit, the Congresswoman was updated on the progress being made in moving OyaGen's drug programs toward clinical development

GeoVax Reports 2013 Third Quarter Financial Results
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today reported financial results and recent developments for the three and nine months ended September 30, 2013.

Corporate Social Responsibility Weekly Recap (November 27, 2013 – December 4, 2013)
The following releases focus on Corporate Social Responsibility and moved during the week of November 27, 2013 – December 4, 2013.

Hepatitis C: Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency
For media outside of the U.S.A., UK and Canada only

Umbrella Research Initiates Coverage on TNI BioTech
TNI BioTech, Inc. (PINKSHEETS: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, is pleased to announce that Umbrella Research has initiated coverage on TNI Biotech, Inc. The full report is posted on the Company web site at http://www.tnibiotech

Medecision Awarded Full NCQA Disease Management Systems Certification
Medecision, the leader in collaborative healthcare management technology, today announced that it has earned National Committee for Quality Assurance (NCQA) Disease Management Systems Certification for the full suite of Aerial™ solutions including Disease Management (DM) Clinical Programs.

GeoVax Announces Full Enrollment of Phase 1 Clinical Trial for 2nd Generation HIV/AIDS Vaccine
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, is pleased to announce full enrollment in a 48 patient Phase 1 trial testing the safety and immunogenicity of its 2nd generation adjuvanted DNA/MVA vaccine for the prevention of HIV infection

As Competitors Pursue Alternatives Medgenics' INFRADURE Gains Prominence for its Potential to Treat Hepatitis
Medgenics' (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained productionand delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into the patient and continuously produces and release the desired protein into the patient's system

Actelion announces acceptance of the New Drug Application for macitentan by the US Food and Drug Administration
Actelion Pharmaceuticals Ltd /Actelion announces acceptance of the New Drug Application for macitentan by the US Food and Drug Administration . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Eileen Koch & Company Client, The MY HERO Project, Bestows Top Awards to Extraordinary Filmmakers and Humanitarians at 8th Annual Film Festival
Last Saturday, 12/15/2012, at the University of Southern California's School of Cinematic Arts, The MY HERO Project's International Film Festival brought together an impressive crowd to applaud the efforts of filmmakers and humanitarians around the world. The non-profit organization is dedicated to connecting and inspiring children across the world through interactive media

GeoVax Labs Featured in Five Publications
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, was featured in five publications during the past two weeks, a period also marked by the observance of World AIDS Day 2012 on December 1.

Avid Bioservices Announces Completion of Facility Upgrades in Response to Increased Demand for Its Contract Manufacturing Services
Avid Bioservices, Inc, a contract manufacturing organization (CMO) focused on the process development and manufacturing of monoclonal antibodies, proteins and enzymes, today announced that its demand for services has reached an all-time high, while projected revenue for its current fiscal year ending April 2013 is expected to surpass $18 million, a 20% increase from the previous fiscal year.

Chanceton Financial Group Limited Completed the Acquisition of 20% Equity Interests in Revenue Synthesis Limited

Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial
Bionor Pharma ASA (OSLO: BIONOR)

GeoVax Labs to Present at Fifth Annual LD Micro Conference
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced that Robert T. McNally, Ph.D., President and CEO, will present at the fifth annual LD Micro Conference on Wednesday, December 5, 2012, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Dr

Immunotech Laboratories Inc. Announces Breakthrough Results for HIV and AIDS Treatment for Terminal Salvage Patients
Immunotech Laboratories, Inc. (PINKSHEETS: IMMB)

Market Research Report -- HIV/AIDS Therapeutics Market to Reach $21.8 Billion by 2018
MarketResearch.com has announced the addition of "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth," to their collection of market research reports.

Mymetics Announces Change of Directors and Management
Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense, to prevent transmission of infectious diseases, announced today the appointment of Ronald Kempers, currently CFO and COO, as President and CEO of Mymetics Corporation effective November 19, 2012. He replaces Dr. Christopher S

Actelion submits the registration dossier for macitentan (Opsumit) to the European Medicines Agency (EMA)
Actelion Pharmaceuticals Ltd /Actelion submits the registration dossier for macitentan (Opsumit) to the European Medicines Agency (EMA) . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Renowned Philanthropist and Infosys Co-Founder N.R. Narayana Murthy Receives Global Humanitarian Honors at The Tech Awards
Indian philanthropist N.R. Narayana Murthy and a dozen innovators from around the world were honored Thursday at The Tech Awards, Silicon Valley's most esteemed program for honoring the people who create pioneering technology to benefit humanity.

Cambridge Heart Reports Results for the Three and Nine Months Ended September 30, 2012
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported results for the three and nine months ended September 30, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on November 14, 2012.

GeoVax Reports 2012 Third Quarter Financial Results
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the nine months ended September 30, 2012 and provided a business update.

Direction Change Ahead, What to Expect - Research & Analysis on Marathon Oil Corporation and Marathon Petroleum Corporation
Moments ago, TradersInsight.net introduced new coverage of Marathon Oil Corporation (NYSE: MRO) and Marathon Petroleum Corporation (NYSE: MPC). Full outlook, analysis and consensus opinion is available to readers via the links below.

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease
For media outside of the U.S.A. , UK and Canada only

Comment on this story

Share